Nasdaq

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Visit neffy.com to “Get neffy Now” and access the comprehensive patient assistance programs available through neffyConnect ARS Pharmaceuticals has also submitted a supplemental New Drug Application ...
Seeking Alpha

ARS Pharmaceuticals Launches Pre-Ordering Services for neffy® to Help Patients Access the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

Patients who already have a prescription can work with their healthcare provider to request neffy through the neffyConnect service and BlinkRx As an additional resource, neffyConnect can guide ...
KTVU

FDA approves neffy nasal spray as alternative to EpiPen

The nasal spray, marked as neffy, is intended as an emergency treatment for severe allergic reactions. Neffy is the first needle-free alternative to shots like EpiPen. The FDA said it approved the ...
Benzinga.com

3SPRY : FDA Approves ARS Pharmaceuticals' Lower Dose Neffy Nasal Spray...

FDA approves Neffy 1 mg for children aged 4+ weighing 15 to <30 kg for allergic reactions. Most insured patients can access Neffy for $25, while cash price is $199 for two doses. Get our list of 10 ...
The Spokesman-Review

FDA approves Neffy, a nasal spray alternative to an EpiPen that does not need a needle to stop an allergic reaction

Those at risk of a severe allergic reaction always have handy an EpiPen just in case. But soon their life might be saved by a spray in the nose rather than a needle to the thigh. Last week the FDA ...
Business Insider

neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy offers a new delivery method for epinephrine in Canada for adults and children (>30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market neffy in Canada ...
Nasdaq

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to ...

SAN DIEGO, March 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves ...
Healio

Q&A: Company seeks to expand neffy FDA approval to more pediatric patients

Please provide your email address to receive an email when new articles are posted on . Children as young as age 10 years are able to self-administer neffy 1 mg. ARS Pharmaceuticals is also working on ...

ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to ...
Seeking Alpha

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the First and Only Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

In addition to its U.S. launch, ARS Pharmaceuticals plans to expand access to EURneffy ® (trade name for neffy in the EU) internationally in partnership with an EU-based pharmaceutical partner. On ...